UPDATED Jun 15, 2024
Companies in consumer staple industries including durables, food, beverage, tobacco, and household and personal products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
LLY * | US$16,390.00 | 4.3% | 113.0% | US$791.0b | US$15,959.67 | PE128.9x | E27.3% | 0.6% | ||
NOVOB N | kr.2,708.33 | 21.7% | 95.4% | kr.4.4t | kr.2,553.29 | PE49.2x | E13.3% | 0.9% | ||
NVO N | kr.2,617.01 | 0.5% | 90.2% | kr.4.4t | kr.2,467.20 | PE49.2x | E13.3% | 0.9% | ||
JNJ * | US$2,675.00 | -1.3% | -4.9% | US$350.3b | US$3,156.13 | PE20.5x | S4.4% | 3.4% | ||
MRK * | US$2,337.01 | -1.6% | 24.4% | US$327.9b | US$2,575.29 | PE142.2x | E23.7% | 2.4% | ||
ABBV * | US$3,119.21 | -0.5% | 32.3% | US$297.7b | US$3,386.61 | PE50x | E23.3% | 3.7% | ||
AZN1 N | UK£2,619.82 | 0% | n/a | UK£193.9b | UK£2,861.61 | PE38.9x | E14.7% | 2.0% | ||
AZN N | UK£1,504.00 | 2.2% | 17.2% | UK£193.9b | UK£1,642.81 | PE38.9x | E14.7% | 2.0% | ||
ROG N | CHF5,123.90 | 3.0% | -4.8% | CHF200.2b | CHF5,754.09 | PE17.2x | E8.5% | 3.9% | ||
TMO * | US$10,580.16 | 2.0% | 15.7% | US$218.4b | US$11,642.18 | PE36.2x | E10.6% | 0.3% | ||
NVS N | CHF1,851.08 | 0% | 8.9% | CHF193.9b | CHF1,920.82 | PE23.9x | E10.2% | 3.4% | ||
NOVN N | CHF1,719.29 | 0% | n/a | CHF180.4b | CHF1,885.96 | PE26.2x | E10.1% | 3.5% | ||
DHR * | US$4,699.00 | 4.3% | 13.4% | US$188.8b | US$5,039.40 | PE46.4x | E13.8% | 0.4% | ||
AMGN * | US$5,185.00 | 0% | 34.6% | US$160.2b | US$5,494.43 | PE42.6x | E18.2% | 3.0% | ||
PFE * | US$506.63 | -3.9% | -26.5% | US$156.0b | US$587.33 | PS2.8x | E30.6% | 6.1% | ||
SAN1 N | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
VRTX * | US$8,821.29 | -1.1% | 48.5% | US$124.1b | US$8,503.66 | PE30.9x | E10.4% | n/a | ||
SNY N | €875.00 | -9.8% | -2.7% | €108.0b | €1,095.31 | PE23.8x | E17.0% | 4.4% | ||
REGN * | US$19,035.51 | 6.3% | 47.6% | US$111.8b | US$19,233.54 | PE29x | E12.5% | n/a | ||
CSL N | AU$3,635.42 | 0% | n/a | AU$145.0b | AU$4,103.81 | PE45.3x | E17.9% | 1.1% | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£72.4b | UK£409.15 | PE16.1x | E12.2% | 3.3% | ||
BMY * | US$764.00 | 0.5% | -31.7% | US$83.5b | US$986.42 | PS1.8x | E44.7% | 5.8% | ||
GSK N | UK£756.56 | 1.0% | n/a | UK£65.4b | UK£960.24 | PE14.6x | E12.3% | 3.6% | ||
GILD * | US$1,185.00 | 5.0% | -12.4% | US$81.1b | US$1,506.25 | PE167.1x | E36.2% | 4.7% |